|
|
Post by itellthefuture777 on Jan 4, 2019 13:57:56 GMT -5
I once was looking at Vermillion when it was .04..supposed to go bankrupt thee next day..but then that night the FDA approved their medical device..and it went over $30..that was 1 device..but it happened to be the only FDA approved Ovarian cancer test in the U.S....I will take a look around...and do some datamining..  True, but just to clarify it did not go from 0.04 to over $30 over night (not that you said it did, but some could have read it that way). It took some months. And with hindsight, it was a speculative bubble. Trading today at 0.40. With a market cap below that of MNKD's. But if your data mining reveals some good picks please do post them for us in the Other Stocks area. Over night it went from .04 to 1.05...then to $5..then $12..then within about 30 days..over $30..If I see something..I'll post a thought..good hunting! |
|
|
|
Post by oldfishtowner on Jan 4, 2019 14:26:31 GMT -5
"Big winner"? Come on. The CC was positive. Castagna et al are developing the right strategies to grow Afrezza sales and the company. But "big winner" is just hype.
It's not clear how much the consolidation of the marketing effort and increased DTC will accelerate script growth. What is clear is that Casatgna is still operating under fiscal constraints, even though these constraints have been somewhat relaxed. Even MK knows that, evident when he made reference to another cash raise.
It is also clear that there are limits to how much the current sales force can do. This was not the first time we heard about physicians telling MNKD they were not seeing sales reps as often as they would like and this was limiting scripts. MNKD needs more cash to hire more sales reps. I have said that before. And because of this, at some point there are diminishing returns as DTC efforts are increased. Castagna probably realizes this and has kept the ad campaign within these limits.
The contract with Kaiser may turn out to be just as important as the sales team adjustments and DTC, who knows?
And for all of the criticism regarding the equity sale, it may be the critical event that changes the company's fortunes and makes the sales team reorganization meaningful and the enhanced DTC possible.
What is important is that things are moving forward. But I don't need the hype from MK. Pumping up expectations only creates disappointment.
|
|
|
|
Post by awesomo on Jan 4, 2019 15:11:09 GMT -5
|
|
|
|
Post by kc on Jan 4, 2019 15:53:31 GMT -5
Transcript from call this Morning.
Michael Castagna
Thank you, Rose, and good morning everybody, and thank you for joining me for a quick investor update. We’re going to be very busy hosting investor and business development meetings around the JPMorgan Healthcare Conference next week in San Francisco. And because we are presenting, we thought it was prudent to update investors on our 2019 strategic imparitives.
The three things I want you to walk away from today’s call is number one; the company is in a solid financial position with enough capital to get up to mid 2020 which will enable us to weather the market turmoil we started to see in December and expect to continue in 2019.
Number two, we will -- have a robust pipeline with seven Technosphere based molecules moving forward that I will share in greater detail. And number three; we are increasing our Afrezza’s position and consumer focus to drive Afrezza uptake in 2019.
Let me start first with financial. The capital raise was important to get done by year-end because we wanted to be able to execute our fully funded 2019 strategic plan. The next likely window that we haven’t yet opened would be March close to our Q4 earnings call which won’t allow us time to adequately fund and execute our plan with confidence given the market volatility we are seeing.
This capital raise was sourced from a strategic investor, existing institutional shareholders and new long term equity shareholders and we’ve had -- and we’ve met with and have been doing -- and will be doing our due diligence over the last 12 months. These investors were interested in making sure we’re able to invest in our 2019 growth plan and carry us in the mid 2020 or longer depending what happens with the outstanding warrants, a further sales trend as well as any potential business development transactions.
Additionally, we were able to work with and establish several new investment bank relationships that we believe will be important as we continued our transformation. We closed 2018 with the lowest amount of debt in over 12 years, and we started the year with approximately $70 million in cash from our balance sheet, the most in three years.
Additionally, we expect $37.5 million in milestones from treprostinil in the next 18 months in addition to further sales continuing to grow as December closed on our highest TRx and dollar sales numbers ever.
We are extremely excited about 2019 and beyond as we continue to see annual sales revenue and unit growth in an industry that is struggling for any growth. We now have the resources to balance the short and long term growth of the company as our capital allocation decisions we make today will go beyond 2019 just like the key decisions we made in late Q4, 2017 to fund the STAT trial, pilot TV and fund our Tret T through Phase 1, help bring us to a very strong close in Q4 of 2018. This resulted in the United Therapeutics deal of $105 million. Our STAT study helping change the recent ADA standards of care, and we now have the resources to move our product through the pipeline and today we are announcing the launch of a major TV campaign using our award winning commercial.
Second, let me talk about our Technosphere pipeline. At the start of the year, we have three products currently tied up through partnerships with the United Therapeutics for PAH and receptor life sciences in the cannabinoid space.
We are moving our own compounds forward throughout 2019. Tret T and recent and further STAT study results have validated our belief that Technosphere technology is a highly differentiated, innovative and unique delivery platform. We anticipate moving the following types of molecules forward.
Number one, a triptan for acute migraine, number two, a 5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Number three, inhaled tobramycin for cystic fibrosis, and the fourth one is an undisclosed compound targeting a large consumer driven market that we are keeping confidential for competitive reasons.
These four molecules are within our current capital allocation for 2019. Our clinical development team is working hard to bring these molecules forward and the opportunity presents itself through partnerships to bring more things forward such as epinephrine that we believe serve an unmet need, but don't meet our screening criteria as I’ve previously talked about. Our website will be updated shortly to reflect these new additions.
Now let me shed some more detail on Afrezza. We believe mealtime is one of the last crusade in the optimal care for diabetes. And based on our recent data presentations and publications, we are confident Afrezza is the best solution for people requiring mealtime control. The continuing glucose monitoring market doubled in size in 2018 and now almost 600,000 people consider a current injectable insulin takes two hours to start to bring down their sugars.
The updated ADA standards of care in December highlighted some of the unique aspects of Afrezza around dosing leading to improved control, and stated we may reduce the rates of hypoglycemia, which has been the Achilles heel of insulin for 100 years. This is why we believe now is the time to invest and raise awareness of Afrezza as our market research and customer meetings confirm the combination of a more focused footprint, new clinical data, increased consumer awareness, ADA guidelines update and continued growth in the continuous glucose monitoring space to drive our success in 2019 and beyond.
We did some due diligence last year, and asked our customers why are we growing faster? And we hear three things. I want to see my sales rep more. Consumers aren't asking for it, and the repair coverage less access. So let me talk to you about these three things and what we’re doing to address them.
To ensure that we deliver on customers seeing the reps more, we exited 14 states at the end of 2018 which unfortunately resulted in a reduction in some of our MannKind employees who worked hard to help people living with diabetes.
Our commercial strategy in 2019 will focus on 30 states that drive over half of the rapid-acting insulin market. This will enable us to shrink the size of existing territories as well as add approximately 15 new cell territories in areas where we are growing. We anticipate positive payer coverage and or/are generally seeing faster uptake of Afrezza. This will provide more face time with the customers and increase top of -- mind awareness that currently drive over 90% of Afrezza sales.
Number two; we are taking a more aggressive approach at increasing
Number two; we are taking a more aggressive approach at increasing consumer awareness. By launching a direct-to-consumer TV campaign, we looked at sales recent product launches with smaller sales footprints with an aggressive DTC approach to benchmark our 2019 strategy. After testing several consumer TV pilots to see what worked best, we feel it's the right time to accelerate our efforts in this area.
We've elevated our strategic communications capabilities for Afrezza by partnering with WPP’s Premier Media health team. CMI Media is the largest healthcare media agency in the U.S. and works with over 50 pharma companies it won't be the lead strategic agency handling our media planning.
Their sister agency group and the world's largest advertising media company in terms of billings will lead media buying. A major television campaign is to launch on January 14th from 26 national cable networks as well as on local TV stations that align to our growing, but targeting salesforce strategy.
The third topic here I want address is payers/patient access. We are continuing to see positive payer coverage as we start out 2019 as evidenced by our recent signing of the contract with Kaiser [ph] and ongoing discussions with other key payers. We currently have 50% of commercial lives with no prior authorization and approximately nine out of 10 commercial lives, commercially insured patients have coverage with Afrezza with or without prior authorization according to fingertip formulary.
You will see and hear about a series of new programs aimed at making sure people who acquired mealtime insulin have access to Afrezza. Next week we are launching a two-in-one card that will enable commercial patients to fill their prescription in the retail pharmacy for as low as $15 despite any payer/competitor driven obstacles that often delay important dreamy [ph] choices as we believe patients should have open access for all unique products and diabetes. As opposed to restricting patient prescriber choice, which ultimately protect monopolies and drive up costs to the healthcare system?
Additionally, we read about the horrible stories of consumers rationing insulin and we could see there are thousands of prescriptions a month where people were paying a significant amount of cash for their injectable rapid acting insulin.
We’d be launching a direct purchase option for Afrezza that eliminates all the middlemen, so we can pass along the savings directly for these patients who are paying cash for the rapid acting injectable insulin, as we want to be part of the solution for the future of healthcare and healthy living.
Two final topics I didn’t address, that are now on top of my mind based on the questions I’ve been receiving are international expansion in pediatrics. We have been working diligently with our partner in Brazil and regulatory authorities to secure our first approval outside the U.S. and hope to have an update for you on this surely as the holidays slowed down our review unfortunately. We need to finish our part one of our pediatric program to file what is known as a PIP in the EU before we can engage in a meaningful filing application for Europe.
We anticipate filing in Canada in the first half of 2019 and meeting with the European regulatory authorities to start a [indiscernible] over there as these are the two most common places where we get requests for Afrezza from our international inquiries.
We know it takes time to gain regulatory approval in these markets and we’ll make appropriate call to look for one go-to-partner ex-U.S. or continue to find key partners in each market like we did with Brazil and India.
We anticipate our pediatric program to be Phase III ready by the end of 2019. We also expect a few additional readouts this year from our One Drop study as well as our investigator trial type 2 patients with Dr. Phil Levine in Baltimore.
We’re excited to see the interim analysis presented at the upcoming scientific conferences in 2019. We thought being able to raise $80 million at an average price of $1.55 when you include the warrants, decreases our dependency on the capital markets. This funds our efforts to continue to grow revenue, manage our expenses and bring on more institutional retail investors.
Additionally, this enables us to focus all of our energy on driving Afrezza growth, moving pipeline products forward as well as other BD opportunities as we continue to shape our culture by retaining our current talent and recruiting the best talent we can find.
In closing, we expect this capital raise will fund MannKind through mid 2020 and we feel confident that raising equity was the best solution for shareholders given the recent debt deals resulted in several companies filing for bankruptcy. And the volatility we see in the equity markets ahead will make it very difficult for companies to obtain funding throughout 2019 as there will be significant needs for capital and not enough capital to fund everyone.
I appreciate your patience and look forward to sharing our Q4 and 2018 performance with you in late February. I’ll now stop and take any questions.
Question-and-Answer Session
|
|
|
|
Post by kc on Jan 4, 2019 15:59:30 GMT -5
Mike's Answer to MK....
Michael Castagna
Thank you, Michael and I appreciate the plethora of questions. I'll try to go through four key ones that I wrote down. The first one is on compensation. I would just say the board and the comp committee meet annually. They benchmark the compensation of all the top officers in the company through an independent third-party and every year that's looked at and will continue to be looked at as we go forward. I don't have much else to say other than that that is handled by the board in an independent way and benchmarked against peer -- peer type companies, and they look at everything that you see that we operate in.
On the second question on dilution, I just want to highlight when we had asked for additional shares previously, it was really get us to the next two, three years, and we weren't sure exactly at that time how much debt we’ll be taken on, how much equity we’d be raising. How we would fix the debt. If you remember the company had almost 200 – over $250 of debt two years ago, a little over two year ago, and now today we sit here with about $105 million. So lowest amount of debt in the last 12 years, that really takes out companies and shareholders unfortunately. And we've been able to navigate a very tight window with some pretty tough restrictions on our cap structure in our company. People don't remember we had anti-dilutive warrants. We had no shares to restructure the balance sheet last year. We were pretty much at a dead end and we were able to navigate through a very tight window and really get through that process.
And so in that when I think about where we are today we structured this deal in a way that would -- we weren't sure where that 230 [ph] warrant would come in April. Would our stock price hit there or not? And we don't want to be -- this goes back to your timing, we don’t want to be dependent on that offering. And we also did not want be dependent on it, right? So you could have waited till March and you could have saw how the stock was trading, but you know if you wanted to fund the pipeline, if you want to fund a major TV campaign, at the time to do that is in Q1 not in Q2 the most TV America watches as in Q1 all the new shows launch in Q1. And you want to keep DTC going and have we waited three months. We just would've lost three more months of window opportunity to drive expansion of Afrezza. And that's really when I talk to investors and I talk to retail people, they want to say, why Afrezza not growing faster. When I say 99% of people who aren't influent, don't even know this product exist. That’s the shame, right? It's a shame on our part. It's a shame on the doctors. It's a shame on the third parties out there that this should at least be an option.
When I talk to JDRF, what are they looking forth, a drug that have less weight gain, less hypo, better time and range. We proved all three of those points in our studies and yet you don't see that being offered consistently to patients. And so we feel it's time that our consumer efforts really spike up. And we spent a good year working through those channels to see which consumer effort will work better than another. And now we take a step back. If the shares expire in April, we'll get back 40 million shares in the last offering in April this year – last year I'm sorry. And by December I do expect our stock price to be above a $1.60 and then that could bring another $40 million which would solve any potential funding issues in 2020. And if it doesn't, worst case scenario we got back now 30, 40 million shares back in our office and we still another 20 some million backing our debt. So there's always ways to restructure debt to get those shares back. So I think from an overall share count we won't be in the position we were in. But we've been able to manage dilution in a way that cleaned up the balance sheet, provide a cash, we now seven compounds to be going down the pipeline and Afrezza is growing and continue to grow for the next 10 plus years. So see nothing slowing that down. So hope it explain a little bit about the dilution. On discount it was in -- the stock was trading at $70 and in a very volatile market. I mean, we were up down, up down and so being able to price that offering at about 8.5% discount for about 15% dilution with a very fair price that we thought balanced shareholder value and making sure we funded 2019.
But the reason and few may not appreciate it, but when we laid out our 2018 plan we expect to finish up the recap by February March timeframe. We scaled the territory to 100 territories. We held these plans. And then we didn't finish up the financial restructuring for lots of reasons until September when we did the United deal. And so then I got beat up on guidance. We got beat up on script growth and vacancies and how many territories are posted, but we couldn't we still think. We manage the budgets very tightly throughout 2018 to get through the year and that wasn't a really fun process to be in.
So this year now we're funded. We've got our plans. We're executing our plan. The team is fully aligned and I feel like we're in the best position between talent, product, positioning and new marketing campaign that’s launching next week, very excited about all that coming together at once. And then I want to add something I didn't talk much about and that's really around expenses. So we'll work with Amphastar, our partner to make sure our influent purchase commitment is consistent with our demand, so that will create some value for us this year to continue to invest in commercial growth. And we also we talked about RLS as one of the seven pipeline compounds because they just raised $30 million. But we didn't talk about as we look out over 2020 and 2021 and 2022 what starts to happen is the pipeline royalties will kick in, the milestone will kick in between India, Brazil, RLS, United Therapeutics, all these new revenue streams will start to pay off over the next 36 months when we look at the future.
And that that will ultimately require less capital raises, require less capital needs and we don't know how many additional pipeline assets we'll be able to fund over the next 18 months or deal that we'll be able to close that will bring in additional cash. So we look at that the -- we now have 18 months in front of us to run the company, to make prudent choices. And we think everything we’re doing will result in additional opportunities and who knows if there'll be another capital raise or not. I mean I can't presuppose what could happen, but I would say at least we're now in control of our destiny. We have no major debts due, and we now can choose to pay things off if we need to, and we can run the company where we have to.
So, I feel very good about the overall process and I feel very good about our future and our employees are very excited about where things are going. So hope you understand some of that. I know it’s not everything you want to hear, but I also want to be transparent and direct with where we think the things are going and the future of the company. So we're excited. We think the market is very volatile this year and we're just glad we don't have to be in the capital markets, it was a significant distraction on my end. I probably spent over 20 red eyes going to New York in the last year. So I don't have to spend time doing that. I do a lot of non-deal roadshows. I'll continue to invest my time with shareholders and listening to them. But most importantly what's important consistent what I hear is show me double digit Afrezza growth consistently quarter over quarter. And that's our main focus on our on our revenue driver. And the second one is can you get more deals done with the pipeline and we're moving those products forward to bring transparency to them as we go forward in 2019.
So I want to thank everybody for their time their patience and the questions. We are very excited we'll have earnings call probably late February and I'll look forward to sharing Q4 in 2018 results with you and any updates we have at that time. Thank you again
|
|
|
|
Post by mnkdfann on Jan 4, 2019 16:10:36 GMT -5
IMO, the conference call was about as good as could be expected.
What would concern me, if I was a worrier (or owned more than the handful of shares I do), would be the financial and approval forecasts. Last year's financial and approval forecasts were IMO pretty bad. Will they really be better this time?
|
|
|
|
Post by mytakeonit on Jan 4, 2019 16:15:41 GMT -5
Sorry but I'm not waking up at 4 a.m. Hawaii time to hear this CC. When I wake up and the share price is sky high ... then I'll rush to hear the CC. Other than that, I'm drinking wine now with no inclination to wake up early. Me neither. I'm in Kauai having a cigar on the deck of my hotel room. A little windy, but anything is better than Minnesota this time of year. See ... if a half naked guy can visit Hawaii ... then the MNKD team should be to afford it. |
|
|
|
Post by mango on Jan 4, 2019 16:43:02 GMT -5
This sounds interesting—
"We’d be launching a direct purchase option for Afrezza that eliminates all the middlemen, so we can pass along the savings directly for these patients who are paying cash for the rapid acting injectable insulin, as we want to be part of the solution for the future of healthcare and healthy living."
|
|
|
|
Post by sportsrancho on Jan 4, 2019 21:00:35 GMT -5
"Big winner"? Come on. The CC was positive. Castagna et al are developing the right strategies to grow Afrezza sales and the company. But "big winner" is just hype.
It's not clear how much the consolidation of the marketing effort and increased DTC will accelerate script growth. What is clear is that Casatgna is still operating under fiscal constraints, even though these constraints have been somewhat relaxed. Even MK knows that, evident when he made reference to another cash raise.
It is also clear that there are limits to how much the current sales force can do. This was not the first time we heard about physicians telling MNKD they were not seeing sales reps as often as they would like and this was limiting scripts. MNKD needs more cash to hire more sales reps. I have said that before. And because of this, at some point there are diminishing returns as DTC efforts are increased. Castagna probably realizes this and has kept the ad campaign within these limits.
The contract with Kaiser may turn out to be just as important as the sales team adjustments and DTC, who knows?
And for all of the criticism regarding the equity sale, it may be the critical event that changes the company's fortunes and makes the sales team reorganization meaningful and the enhanced DTC possible.
What is important is that things are moving forward. But I don't need the hype from MK. Pumping up expectations only creates disappointment.
Geez how many times today are you going to say this ? ...then just block me and you wont to see anymore of his posts. |
|
|
|
Post by brotherm1 on Jan 4, 2019 21:40:04 GMT -5
This stock and company needs all the positive press it can get fishtowner. We need people like MK. Why is that so hard for you to understand?
|
|
|
|
Post by brotherm1 on Jan 4, 2019 21:47:26 GMT -5
And we need people like Sports who has been dedicated to getting out the good word about our undervalued investment - and without any pay. So take a chill pill
|
|
|
|
Post by lakers on Jan 15, 2019 5:05:40 GMT -5
“We have been working diligently with our partner in Brazil and regulatory authorities to secure our first approval outside the U.S. and hope to have an update for you on this surely as the holidays slowed down our review unfortunately. We need to finish our part one of our pediatric program to file what is known as a PIP in the EU before we can engage in a meaningful filing application for Europe.We anticipate filing in Canada in the first half of 2019 and meeting with the European regulatory authorities to start a [indiscernible] over there as these are the two most common places where we get requests for Afrezza from our international inquiries. We know it takes time to gain regulatory approval in these markets and we’ll make appropriate call to look for one go-to-partner ex-U.S. or continue to find key partners in each market like we did with Brazil and India.
We anticipate our pediatric program to be Phase III ready by the end of 2019. We also expect a few additional readouts this year from our One Drop study as well as our investigator trial type 2 patients with Dr. Phil Levine in Baltimore.
We’re excited to see the interim analysis presented at the upcoming scientific conferences in 2019.” Superiority Study:Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients clinicaltrials.gov/ct2/show/NCT03324776?term=Afrezza&rank=1Principal Investigator: Philip Levin, MD Senior Director of MODEL Clinical Research Primary Outcome Measures : Percentage change from baseline HbA1c [ Time Frame: 3 months ] Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications. Secondary Outcome Measures : Percentage of patients having HbA1c under 7% [ Time Frame: 3 months ] Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications. Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS [ Time Frame: 3 months ] Demonstrate that the addition of mealtime Afrezza can lower blood glucose in uncontrolled type 2 diabetes patients. A positive outcome could change SOC, Label, results in new favorable publications. Afrezza Safety and Pharmacokinetics Study in Pediatric Patients clinicaltrials.gov/ct2/show/NCT02527265?term=Afrezza&rank=5Pediatric investigation plans (PIP): questions and answers www.ema.europa.eu/en/human-regulatory/research-development/paediatric-medicines/paediatric-investigation-plans/paediatric-investigation-plans-questions-answersThe milestones related to Trep-T are divided into 6 categories Milestone A is $12.5 million Milestone B is $12.5 million Milestone C is $12.5 million Milestone D is $12.5 million Milestone E is $15 million Milestone F is $15 million Milestone Payments (A) through (D) shall be made no more than once (and each only upon the first achievement of the corresponding milestone), irrespective of how many Products achieve the corresponding milestone. Milestone Payments (E) and (F) above may be paid more than once (i.e., if there are multiple Optioned Agents), but each shall be paid only once for the first Optioned Product for each Optioned Agent that reaches the corresponding milestone. No unachieved Milestone Payments shall accrue and be due if notice has been given by United Therapeutics for termination of the Agreement seekingalpha.com/article/4218970 A+B+C+D = $50M for Trep-T which may have multiple products. E+F = $30M per first Optioned Product for each Optioned Agent which may spawn multiple products plus $10M upfront for each Optioned Agent. MC mentioned $37.5 M over 18 mos refered to A+B+C. Superiority Study:A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone clinicaltrials.gov/ct2/show/NCT03313960?term=Afrezza+one+drop&cntry=US&rank=1Detailed Description: Eligible participants (N=400) with an A1c > 7.0% already prescribed a rapid-acting insulin will be randomized to one of two groups: (1) One Drop | Premium 'On Track' (i.e., use the One Drop | Mobile app with in-app diabetes education accredited by the American Diabetes Association with supplemental Afrezza content and a live Certified Diabetes Educator messaging in the app, the 'Chrome' Bluetooth-connected blood glucose meter that uploads blood glucose values in the app, and 150 test strips per month) in combination with Afrezza treatment (n=200) or (2) One Drop | Premium 'On Track' plus their current rapid-acting insulin (n=200). Primary Outcome Measures : Hemoglobin A1c [ Time Frame: 3 months ] 3-month between-group change in A1c assessed by a central lab Secondary Outcome Measures : Insulin Device Satisfaction [ Time Frame: 3 months ] Within- and between-group change in insulin device satisfaction assessed by the Insulin Device Satisfaction Survey (IDSS) Treatment Adherence [ Time Frame: 3 months ] Within- and between-group change in treatment adherence assessed by the Adherence to Refills and Medications Scale for Diabetes (ARMS-D) and the Summary of Diabetes Self-care Activities Medications Subscale administered for each oral diabetes medication (SDSCA-MS) and insulin in the regimen (SDSCA-IS). Self-care [ Time Frame: 3 months ] Within- and between-group change in self-care assessed by the SDSCA's other subscales Health-related Productivity [ Time Frame: 3 months ] Within- and between-group change in health-related productivity assessed by the Work Productivity and Activity Impairment measure (WPAI). Health-related Quality of Life [ Time Frame: 3 months ] Within- and between-group change in health-related quality of life assessed by the Centers for Disease Control Health-related Quality of Life-14 (CDC HRQOL-14) and life satisfaction assessed by the Cantril Self-Anchoring Ladder of Life Satisfaction. |
|
|
|
Post by ktim on Jan 15, 2019 5:25:11 GMT -5
And we need people like Sports who has been dedicated to getting out the good word about our undervalued investment - and without any pay. So take a chill pill Kudos for efforts to promote Afrezza, which should be promoted. But history of getting out word about "undervalued" investment has led to a lot of people suffering significant loses... as the word about being undervalued has existed since MNKD has been at split adjusted price of over $50. |
|
|
|
Post by akemp3000 on Jan 15, 2019 8:08:27 GMT -5
This remains an undervalued investment that has led to losses for "Traders". Investors" however have not yet lost a penny, unless they've sold and moved on in which case, why be here? It truly has been a long haul but MNKD fortunately now has a new management team and is finally moving in the right direction.
|
|
|
|
Post by prcgorman2 on Jan 15, 2019 10:19:15 GMT -5
I don't believe I've ever heard Dr. Castagna utter the word "epic", but if MNKD manages to be profitable before 2021 I might use the word to describe his leadership. I sometimes wonder if he isn't God's gift to investors (and some might say traders too after the last dilution). I trust Dr. Castagna's experience and abilities. Even the fact that I can use the title of "Doctor" when referring to him is impressive since he annexed this degree to his already impressive academic accomplishments while CEO of a pharma startup. The man has chops, and I'll give him props.
|
|
